Cargando…

Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic

Cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer. The standard curative treatment is surgical resection, but the treatment of locally advanced and metastatic disease apart from radiotherapy is currently based on cemiplimab. Cemiplimab has demonstrated eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Pabianek, Marta, Lesiak, Aleksandra, Nejc, Dariusz, Kuncman, Łukasz, Narbutt, Joanna, Skibińska, Małgorzata, Ciążyńska, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600858/
https://www.ncbi.nlm.nih.gov/pubmed/36290893
http://dx.doi.org/10.3390/curroncol29100616
_version_ 1784816933448712192
author Pabianek, Marta
Lesiak, Aleksandra
Nejc, Dariusz
Kuncman, Łukasz
Narbutt, Joanna
Skibińska, Małgorzata
Ciążyńska, Magdalena
author_facet Pabianek, Marta
Lesiak, Aleksandra
Nejc, Dariusz
Kuncman, Łukasz
Narbutt, Joanna
Skibińska, Małgorzata
Ciążyńska, Magdalena
author_sort Pabianek, Marta
collection PubMed
description Cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer. The standard curative treatment is surgical resection, but the treatment of locally advanced and metastatic disease apart from radiotherapy is currently based on cemiplimab. Cemiplimab has demonstrated efficacy in the treatment of advanced and metastatic cSCC in clinical trials, although real-world data are still limited. We present four cases of cSCC, which showed a tremendous response to cemiplimab—one patient achieved complete response and three of them achieved partial response. Immunotherapy with cemiplimab, a recently approved PD1 inhibitor, is an important addition to the cutaneous oncology therapeutic options that may be considered in patients with advanced disease not amenable to surgery or radiotherapy. In all four cases, the patients postponed visits to the doctor because of the fear of SARS-CoV-2 infection or for administrative and organizational reasons declared difficult access to doctors caused by the pandemic.
format Online
Article
Text
id pubmed-9600858
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96008582022-10-27 Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic Pabianek, Marta Lesiak, Aleksandra Nejc, Dariusz Kuncman, Łukasz Narbutt, Joanna Skibińska, Małgorzata Ciążyńska, Magdalena Curr Oncol Case Report Cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer. The standard curative treatment is surgical resection, but the treatment of locally advanced and metastatic disease apart from radiotherapy is currently based on cemiplimab. Cemiplimab has demonstrated efficacy in the treatment of advanced and metastatic cSCC in clinical trials, although real-world data are still limited. We present four cases of cSCC, which showed a tremendous response to cemiplimab—one patient achieved complete response and three of them achieved partial response. Immunotherapy with cemiplimab, a recently approved PD1 inhibitor, is an important addition to the cutaneous oncology therapeutic options that may be considered in patients with advanced disease not amenable to surgery or radiotherapy. In all four cases, the patients postponed visits to the doctor because of the fear of SARS-CoV-2 infection or for administrative and organizational reasons declared difficult access to doctors caused by the pandemic. MDPI 2022-10-16 /pmc/articles/PMC9600858/ /pubmed/36290893 http://dx.doi.org/10.3390/curroncol29100616 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Pabianek, Marta
Lesiak, Aleksandra
Nejc, Dariusz
Kuncman, Łukasz
Narbutt, Joanna
Skibińska, Małgorzata
Ciążyńska, Magdalena
Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
title Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
title_full Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
title_fullStr Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
title_full_unstemmed Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
title_short Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
title_sort promising immune treatment of advanced cutaneous squamous cell carcinoma with cemiplimab—real-world experience in the global sars-cov-2 pandemic
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600858/
https://www.ncbi.nlm.nih.gov/pubmed/36290893
http://dx.doi.org/10.3390/curroncol29100616
work_keys_str_mv AT pabianekmarta promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic
AT lesiakaleksandra promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic
AT nejcdariusz promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic
AT kuncmanłukasz promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic
AT narbuttjoanna promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic
AT skibinskamałgorzata promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic
AT ciazynskamagdalena promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic